Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186763 | 1.00 | DUT (0.44) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL26439425 | 0.93 | PLA2G2A (0.42) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL4192561 | 0.85 | DUT (0.39) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL4192567 | 0.85 | DUT (0.39) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL13377619 | 0.84 | DUT (0.41) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL8204874 | 0.84 | DUT (0.39) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL5699551 | 0.83 | DUT (0.40) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL4763266 | 0.83 | DUT (0.40) | DUTKIF11PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL8860746 | 0.81 | CYP1A2 (0.36) | DUTCYP2C9CYP2C19ALDH1A1RECQL | |
| SCHEMBL4762320 | 0.81 | DUT (0.39) | DUTKIF11PLA2G2APLA2G10PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341927-B1 | METHOD OF PREPARING 3-¬2-{(METHYLSULFONYL)OXY}ETHOXY|-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE | PPG IND OHIO INC (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1341927-A1 | METHOD OF PREPARING 3- 2- (METHYLSULFONYL)OXY ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE | PPG Industries Ohio, Inc. (US) | 2003-09-10 | — | — | EP | claimed |
| WO-2002059342-A1 | METHOD OF PREPARING 3-[2-{(METHYLSULFONYL)OXY}ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE | PPG INDUSTRIES OHIO, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| US-6300106-B1 | FORMING S-ISOMER OR R-ISOMER OF (3,6-DIHYDRO-2H-PYRAN-2-YL)-METHANOL VIA A PROCESS WHICH PRODUCES A RACEMIC MIXTURE OF INTERMEDIATE REACTION PRODUCTS, RESOLVING TO SELECTIVELY PRODUCE S ISOMER | PPG INDUSTRIES OHIO, INC. | 2001-10-09 | — | — | US | claimed |
| US-20260042778-A1 | Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof | 4M THERAPEUTICS INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-1061062-B1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVES | DAISO CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1341927-B1 | METHOD OF PREPARING 3-¬2-{(METHYLSULFONYL)OXY}ETHOXY|-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE | PPG IND OHIO INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20040024261-A1 | Process for preparing butanetriol derivative | DAISO CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6620977-B1 | Reacting 1,2,4-butanetriol in multiple steps with specified reagents using selective protection and deprotection of hydroxyl groups | DAISO CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1341927-A1 | METHOD OF PREPARING 3- 2- (METHYLSULFONYL)OXY ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE | PPG Industries Ohio, Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002059342-A1 | METHOD OF PREPARING 3-[2-{(METHYLSULFONYL)OXY}ETHOXY]-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE | PPG INDUSTRIES OHIO, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| US-6300106-B1 | FORMING S-ISOMER OR R-ISOMER OF (3,6-DIHYDRO-2H-PYRAN-2-YL)-METHANOL VIA A PROCESS WHICH PRODUCES A RACEMIC MIXTURE OF INTERMEDIATE REACTION PRODUCTS, RESOLVING TO SELECTIVELY PRODUCE S ISOMER | PPG INDUSTRIES OHIO, INC. | 2001-10-09 | — | — | US | disclosed |
| US-5665877-A | Synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0776899-A1 | Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1997-06-04 | — | — | EP | disclosed |
| EP-0776895-A1 | Protein kinase C inhibitor | ELI LILLY AND COMPANY (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1997018809-A1 | PROTEIN KINASE C INHIBITOR | ELI LILLY AND COMPANY (US) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997019080-A1 | NOVEL INTERMEDIATES AND THEIR USE TO PREPARE N,N'-BRIDGED BISINDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1997-05-29 | — | — | WO | disclosed |
| US-5614647-A | Intermediates for the synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| US-5541347-A | Synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0657411-A1 | Improved synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042778-A1 | Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof | GSK3B, GSK3A, LRRK2 | DUT 4665/4885KIF11 3811/4885PLA2G2A 4443/4885 |
| US-20040024261-A1 | Process for preparing butanetriol derivative | CYP4B1, CYP11B2, CYP11B1 | DUT 3136/4885KIF11 1774/4885PLA2G2A 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.